Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition

  • STATUS
    Recruiting
  • days left to enroll
    88
  • participants needed
    266
  • sponsor
    Sun Yat-sen University
Updated on 19 February 2024
nasopharyngeal carcinoma
karnofsky performance status
carcinoma
liver disease
malnutrition
nutritional support
renal function test
intensity-modulated radiation therapy
endocrine disease
digestive system disease
cisplatin

Summary

This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy of standard nutrition treatment versus conventional nutrition treatment in local advanced nasopharyngeal carcinoma patients.

Details
Condition Carcinoma, vulvar dysplasia and carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Cancer, Nutrition Therapy, Nutritional Support, vulvar dysplasia and carcinoma
Age 18-65 years
Treatment Cisplatin, Intensity modulated radiation therapy, Standardized nutrition therapy
Clinical Study IdentifierNCT04436965
SponsorSun Yat-sen University
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III)
All gendersrange from 1865 years old
Karnofsky performance status(KPS) 80
Clinical stage III~IVa(AJCC/UICC 8th)
Without significant digestive system diseasenutritional and metabolic diseases or endocrine disease
Without significant cardiacrespiratorykidney or liver disease
Not received radiotherapy, chemotherapy and other anti-tumor treatment(including immunotherapy)
White blood cell(WBC) count 4109/L, neutrophile granulocyte(NE) count 1.5109/L, Hemoglobin(HGB) 9g/L, platelet(PLT) count 100109/L
Total bilirubin(TBIL)alanine aminotransferase (ALT) or aspartate aminotransferase(AST) 2.5upper limit of normal(ULN)
Adequate renal function: BUN/CRE 1.5ULN or endogenous creatinine clearance 60ml/min (Cockcroft-Gault formula)
No contraindications to chemotherapy or radiotherapy
Inform consent form

Exclusion Criteria

Have some PEG/PEJ contraindications, such as coagulopathy, recent anticoagulant medications and aspirin, gastric ulcer or history of gastric bleeding, portal hypertension combined with abdominal and esophageal fundal varices, pyloric obstruction due to residual stomach under the costal arch after various major gastrectomy or various reasons
Distance metastases
Have or are suffering from other malignant tumors
Participating in other clinical trials
Drug or alcohol addition
Do not have full capacity for civil acts
Mental disorder
Pregnancy or lactation
Severe complication, eg, uncontrolled hypertension
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.